Glukoza Hztm

Glukoza Hztm is an intravenous preparation that contains glucose monohydrate as its active ingredient. The product is supplied in a formulation intended for parenteral administration, with the specific strength and dosage form not disclosed in the available data. Marketed within the European Union, Glukoza Hztm is classified under the broader category of glucose solutions used in clinical settings for energy provision and fluid balance.

Glukoza Hztm is employed in medical practice primarily as a source of readily available carbohydrate and as part of fluid therapy. It may be considered in the following situations:

- Treatment of hypoglycemia when oral intake is not feasible. - Provision of caloric support during peri‑operative fasting. - Maintenance of plasma osmolarity in patients receiving intravenous fluids. - Support for patients with increased metabolic demand, such as trauma or severe infection. - Adjunct to electrolyte solutions to prevent dilutional hyponatremia.

Glukoza Hztm, like other intravenous glucose solutions, can be associated with a range of observed effects. These are typically categorized by frequency and clinical significance.

Common: - Transient hyperglycemia, especially in patients with impaired insulin response. - Mild local irritation at the infusion site. - Fluid overload when administered in large volumes. - Electrolyte shifts, particularly sodium and potassium changes.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypoglycemia rebound after abrupt discontinuation. - Hyperosmolar hyperglycemic state in susceptible individuals. - Allergic or anaphylactoid reactions to formulation excipients.

When considering Glukoza Hztm for intravenous use, clinicians should observe several precautionary measures to minimize risk:

- Assess baseline blood glucose and monitor levels frequently during infusion. - Evaluate fluid status to avoid volume overload, especially in patients with cardiac or renal impairment. - Review patient history for diabetes mellitus or disorders of carbohydrate metabolism. - Use appropriate infusion rates to prevent rapid shifts in plasma osmolarity. - Verify compatibility with other intravenous medications before co‑administration. - Document any adverse reactions promptly and adjust therapy as needed.

Glukoza Hztm may interact with other agents administered intravenously or orally. Awareness of these interactions helps ensure safe combined therapy.

Avoid: - Co‑administration with high‑dose insulin without close glucose monitoring, due to risk of severe hypoglycemia. - Simultaneous infusion of potassium chloride solutions, which can exacerbate hyperkalemia when combined with glucose‑induced insulin release.

Use with caution: - Concurrent use of diuretics, which may alter fluid balance and electrolyte status. - Administration alongside corticosteroids, which can increase blood glucose levels. - Combination with other carbohydrate‑containing solutions, to prevent excessive caloric load. - Use in patients receiving total parenteral nutrition, requiring careful calculation of total glucose input.